Psoriatic Arthritis – Unmet Need – Detailed, Expanded Analysis (US/EU)
TNF-alpha inhibitors continue to be the preferred choice to treat psoriatic arthritis (PsA) following failure on conventional DMARDs. However, other biologics such as IL-17 inhibitors (e.g., Cosentyx, Taltz), the IL-12/23 inhibitor Stelara, IL-23 inhibitors (e.g., Tremfya), and targeted oral therapies (e.g., Xeljanz, Rinvoq) have begun to chip away at the TNF-alpha inhibitors’ patient share. Understanding the underlying unmet need in the treatment of PsA, as well as the factors that can differentiate products from one another, can determine an agent’s success in this competitive space. This report presents the key unmet needs in the treatment of PsA and provides the tools to make strategic decisions and assessments pertaining to this therapy market.
QUESTIONS ANSWERED
- What are the treatment drivers and goals for PsA?
- What drug attributes are key influences, which have limited impact, and which are hidden opportunities?
- How do current therapies perform on key treatment drivers and goals for PsA?
- What are the prevailing areas of unmet need and opportunity in PsA?
- What trade-offs across different clinical attributes and price are acceptable to U.S. and European rheumatologists and dermatologists for a hypothetical new PsA drug?
PRODUCT DESCRIPTION
Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 61 U.S. and 34 European rheumatologists and dermatologists fielded in February 2023
Key companies: AbbVie, Amgen, Pfizer, Janssen, Novartis, Eli Lilly
Key drugs: Humira, Cosentyx, Taltz, Stelara, Tremfya, Xeljanz, Rinvoq
Table of contents
- Psoriatic Arthritis - Unmet Need - Detailed, Expanded Analysis (US/EU)
- Executive summary
- Unmet Need - Psoriatic arthritis - executive summary - May 2023
- Introduction
- Overview
- Methodology
- Rationale for treatment drivers and goals selection
- Rationale for drug selection
- Products for psoriatic arthritis and rationale for drug selection
- Treatment drivers and goals
- Key findings: attribute importance
- Relative importance of efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to surveyed rheumatologists' and dermatologists' prescribing decisions in psoriatic arthritis
- Importance of efficacy attributes to prescribing decisions in psoriatic arthritis: United States
- Importance of efficacy attributes to prescribing decisions in psoriatic arthritis: Europe
- Importance of safety and tolerability attributes to prescribing decisions in psoriatic arthritis: United States
- Importance of safety and tolerability attributes to prescribing decisions in psoriatic arthritis: Europe
- Importance of convenience of administration attributes to prescribing decisions in psoriatic arthritis: United States
- Importance of convenience of administration attributes to prescribing decisions in psoriatic arthritis: Europe
- Importance of nonclinical factors to prescribing decisions in psoriatic arthritis: United States
- Importance of nonclinical factors to prescribing decisions in psoriatic arthritis: Europe
- Key findings: stated vs. derived importance
- Stated vs. derived importance of key efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to prescribing decisions in psoriatic arthritis: United States
- Stated vs. derived importance of key efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to prescribing decisions in psoriatic arthritis: Europe
- Product performance against treatment drivers and goals
- Key findings
- Overall performance of key therapies for psoriatic arthritis: United States
- Overall performance of key therapies for psoriatic arthritis: Europe
- Mean overall performance of key therapies for psoriatic arthritis: United States and Europe
- Relative performance of key therapies for psoriatic arthritis across select efficacy attributes: United States
- Relative performance of key therapies for psoriatic arthritis across select efficacy attributes: Europe
- Relative performance of key therapies for psoriatic arthritis across select safety and tolerability attributes: United States
- Relative performance of key therapies for psoriatic arthritis across select safety and tolerability attributes: Europe
- Relative performance of key therapies for psoriatic arthritis across select convenience of administration attributes: United States
- Relative performance of key therapies for psoriatic arthritis across select convenience of administration attributes: Europe
- Relative performance of key therapies for psoriatic arthritis across select nonclinical attributes: United States
- Relative performance of key therapies for psoriatic arthritis across select nonclinical attributes: Europe
- Assessment of unmet need
- Key findings: unmet need in psoriatic arthritis
- Surveyed rheumatologists and dermatologistsu2019 satisfaction with the performance of key therapies for psoriatic arthritis on efficacy, safety and tolerability, convenience of administration, and nonclinical factors: United States
- Surveyed rheumatologists and dermatologistsu2019 satisfaction with the performance of key therapies for psoriatic arthritis on efficacy, safety and tolerability, convenience of administration, and nonclinical factors: Europe
- Surveyed rheumatologists and dermatologists' ascribed level of unmet need across key efficacy attributes in psoriatic arthritis: United States
- Surveyed rheumatologists and dermatologists' ascribed level of unmet need across key efficacy attributes in psoriatic arthritis: Europe
- Surveyed rheumatologists and dermatologists' ascribed level of unmet need across key safety and tolerability attributes in psoriatic arthritis: United States
- Surveyed rheumatologists and dermatologists' ascribed level of unmet need across key safety and tolerability attributes in psoriatic arthritis: Europe
- Surveyed rheumatologists and dermatologists' ascribed level of unmet need across key convenience of administration attributes in psoriatic arthritis: United States
- Surveyed rheumatologists and dermatologists' ascribed level of unmet need across key convenience of administration attributes in psoriatic arthritis: Europe
- Surveyed rheumatologists and dermatologists' ascribed level of unmet need across key nonclinical factors in psoriatic arthritis: United States
- Surveyed rheumatologists and dermatologists' ascribed level of unmet need across key nonclinical factors in psoriatic arthritis: Europe
- Key findings: unmet need in psoriatic arthritis and related indications
- Surveyed rheumatologists and dermatologists' ascribed level of unmet need in psoriatic arthritis and related indications: United States
- Surveyed rheumatologists and dermatologists' ascribed level of unmet need in psoriatic arthritis and related indications: Europe
- Opportunity analysis
- Areas of opportunity in the PsA market and emerging therapy insights
- Opportunity: a more-efficacious oral targeted synthetic DMARD
- Opportunity: an agent that is more efficacious in reducing musculoskeletal disease activity
- Opportunity: a novel agent that improves patients' quality of life
- Areas of opportunity in the PsA market and emerging therapy insights
- Target product profiles
- Assessing drug development opportunities
- Target product profile methodology
- Attributes and attribute levels
- Attribute importance and part-worth utilities
- PsA target product profile: attribute importance
- ACR 50 response at week 24 (% of patients, placebo-adjusted)
- PASI 75 response at week 24 (% of patients, placebo-adjusted)
- Decrease in HAQ-DI score at week 24 (baseline-normalized, placebo-adjusted)
- % of patients achieving MDA at 16 weeks (placebo-adjusted)
- Rate of serious infections (per 100 patient-years, placebo-adjusted)
- Medication possession ratio (MPR)
- Price per day (relative to Humira)
- Conjoint analysis-based simulation of a market scenario
- PsA market simulation: share of preference of target product profiles included in the market scenario
- PsA market simulation: likelihood to prescribe of target product profiles included in the market scenario
- PsA market simulation: target product profiles included in the market scenario
- Appendix
- Key abbreviations
- Bibliography
- Executive summary
Rohit Rout, M.Pharm., Research Associate, Immune and Inflammation. Mr. Rout joined as an intern on the China-In-Depth team at Clarivate, where he performed secondary market research for China’s biopharmaceutical market. Before joining Clarivate, he was an associate scientist in the biopharmaceutics (IVIVC) department at Lupin Pvt. Ltd. He holds an M.Pharm. degree in pharmaceutics from the Birla Institute of Technology and Science in Pilani, India.